Evidence map›Paper›PMID 28905282›Full record

ReviewInvestigational new drugs2017

Comparison of reporting phase I trial results in ClinicalTrials.gov and matched publications.

D Shepshelovich, H Goldvaser, L Wang, A R Abdul Razak, P L Bedard

Abstract readComparative StudyReview
PubMed Publisher
In one paragraph

Review in Investigational new drugs, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Observational
  4. Review
  5. Observational
  6. Observational
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

D ShepshelovichPrincess Margaret Cancer Centre, Division of Medical Oncology and Hematology, University Health Network, 7-723 700 University Avenue, Toronto, ON, M5G2M9, Canada.
H GoldvaserPrincess Margaret Cancer Centre, Division of Medical Oncology and Hematology, University Health Network, 7-723 700 University Avenue, Toronto, ON, M5G2M9, Canada.
L WangPrincess Margaret Cancer Centre, Division of Medical Oncology and Hematology, University Health Network, 7-723 700 University Avenue, Toronto, ON, M5G2M9, Canada.
A R Abdul RazakPrincess Margaret Cancer Centre, Division of Medical Oncology and Hematology, University Health Network, 7-723 700 University Avenue, Toronto, ON, M5G2M9, Canada.
P L BedardPrincess Margaret Cancer Centre, Division of Medical Oncology and Hematology, University Health Network, 7-723 700 University Avenue, Toronto, ON, M5G2M9, Canada. Philippe.Bedard@uhn.ca.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background Data on completeness of reporting of phase I cancer clinical trials in publications are lacking. Methods The ClinicalTrials.gov database was searched for completed adult phase I cancer trials with reported results. PubMed was searched for matching primary publications published prior to November 1, 2016. Reporting in primary publications was compared with the ClinicalTrials.gov database using a 28-point score (2=complete; 1=partial; 0=no reporting) for 14 items related to study design, outcome measures and safety profile. Inconsistencies between primary publications and ClinicalTrials.gov were recorded. Linear regression was used to identify factors associated with incomplete reporting. Results After a review of 583 trials in ClinicalTrials.gov , 163 matching primary publications were identified. Publications reported outcomes that did not appear in ClinicalTrials.gov in 25% of trials. Outcomes were upgraded, downgraded or omitted in publications in 47% of trials. The overall median reporting score was 23/28 (interquartile range 21-25). Incompletely reported items in >25% publications were: inclusion criteria (29%), primary outcome definition (26%), secondary outcome definitions (53%), adverse events (71%), serious adverse events (80%) and dates of study start and database lock (91%). Higher reporting scores were associated with phase I (vs phase I/II) trials (p<0.001), multicenter trials (p<0.001) and publication in journals with lower impact factor (p=0.004). Conclusions Reported results in primary publications for early phase cancer trials are frequently inconsistent or incomplete compared with ClinicalTrials.gov entries. ClinicalTrials.gov may provide more comprehensive data from new cancer drug trials.

Indexed as

Clinical Trials, Phase I as TopicDatabases, FactualHumansMedical OncologyPeer Review, ResearchResearch DesignCancerClinicalTrials.govPhase IPublicationsReporting

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.